Vimseltinib for treating Tenosynovial Giant Cell Tumour

Vimseltinib is in development to treat tenosynovial giant cell tumour (TGCT) in adults. TGCTs are rare but non-cancerous tumours that develop in tissues around joints. TGCTs can be diffuse, meaning the tumour affects most of a large joint (e.g., knee), or localised, meaning the tumour is limited to a specific area of the joint (normally smaller joints such as toes). Symptoms may vary depending on the location of the TGCT but commonly include pain, swelling, and limited movement in affected joints. Surgery is often the primary treatment, but sometimes the tumours can come back, especially in larger joints like the knees. If not treated properly, they can lead to joint damage and the joint may require amputation. Patients who aren’t eligible for surgery currently have no treatment options.